Health & pharmaceuticals news

Latest breaking stories, features and analysis

Deutsche Bank: Moderna shares could slide sharply to $250
  • Deutsche Bank initiates Moderna with a "sell" rating with a price target of $250.
  • Analyst Papadakis says the firm has bleak prospects in the post-pandemic world.
  • Shares of the biotech firm are down more than 30% from their year-to-date high.
October 22, 2021

Market analysis

Sight Sciences stock prediction as shares spike 12% on positive TearCare data
October 21, 2021
Is it safe to buy Biogen stock after boosting guidance ahead of Street forecasts?
October 20, 2021
Is it too late to buy Abbott shares after raising FY2021 earnings guidance?
October 20, 2021
Should you buy or sell JNJ shares after delivering mixed Q3 results?
October 19, 2021

More breaking stories

October 20, 2021
October 20, 2021
October 20, 2021
October 20, 2021
October 19, 2021
October 19, 2021
October 19, 2021
October 15, 2021
October 15, 2021
October 14, 2021
October 14, 2021
October 14, 2021
October 13, 2021
October 13, 2021
October 12, 2021
October 11, 2021
October 11, 2021
October 11, 2021
October 11, 2021
October 11, 2021
October 8, 2021
October 8, 2021